Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea on Mounjaro is real, but it is also manageable — and in most cases it settles on its own as your body adjusts. The most effective way to stop sickness on Mounjaro is to slow down your eating, avoid fatty or rich food around injection day, and keep portions smaller than you might expect to need. Most people find the discomfort is sharpest in the first week or two after starting or after each dose increase, then fades noticeably. Mounjaro (tirzepatide) is a prescription-only medicine; a GPhC-registered prescriber reviews every patient before and throughout treatment, and they are the right person to talk to if nausea is severe or persistent. The NHS tirzepatide page includes a full side-effect profile alongside practical self-care advice.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Many people who experience sickness in the first few weeks assume it signals a problem, that their body is rejecting the medicine or that they should stop. That's usually the wrong conclusion. Nausea is a direct pharmacological effect of how tirzepatide works: it slows the rate at which food leaves your stomach (gastric emptying) and signals the brain's appetite centres through both the GIP and GLP-1 pathways. Feeling queasy, particularly after eating, is in part the medicine doing what it is supposed to do.
The titration schedule is designed around this. Treatment begins at 2.5 mg not because that dose drives significant weight loss, but because it lets your digestive system adjust before each step up. Most people who push through the early weeks (with the self-care adjustments below) find the sickness settles within days to two weeks of each increase. Knowing that timeline in advance makes it considerably easier to sit with.
If you are finding nausea on tirzepatide overwhelming rather than merely unpleasant, that is worth raising with your prescriber before you assume the medicine is a bad fit. A slower titration pace is sometimes the right clinical call, and it is a conversation, not a failure.
The adjustments that make the most consistent difference are less about what you eat and more about how. Eating slowly is the single most useful change most people can make. Tirzepatide is already slowing gastric emptying; adding a large meal on top of that creates pressure and nausea. Smaller plates, taken slowly, sidestep a lot of it.
Specific things worth trying on and around injection day:
Over-the-counter antiemetics are sometimes used, but discuss this with your prescriber or pharmacist before starting them. Some interact with other medicines or mask symptoms that should be monitored. You can find broader information on what side effects Mounjaro can cause and how they typically present, which helps you distinguish ordinary adjustment nausea from something that needs clinical input.
Self-management tips are appropriate for the GI discomfort that is common, predictable and mild-to-moderate. There are circumstances where the advice changes entirely.
Severe vomiting that prevents you keeping fluids down carries a real risk of dehydration, which in turn can stress the kidneys, a concern the MHRA's Yellow Card reporting scheme documents for GLP-1 medicines. If you cannot keep water down for more than a few hours, contact a healthcare professional the same day rather than waiting it out.
Severe and persistent stomach pain that radiates to your back (with or without vomiting) is a different matter. The MHRA has specifically highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and that presentation is the key symptom pattern to watch for. It is not the same as ordinary Mounjaro sickness and it warrants urgent medical attention, not dietary adjustments.
Anyone whose nausea is severe enough to affect their day-to-day life, or that has not improved after two weeks on a stable dose, should speak to their prescriber. At nume, aftercare is available seven days a week precisely because these questions arise at inconvenient moments, not just on weekday afternoons.
There is a practical side to this conversation that doesn't always come up. Managing sickness from Mounjaro well often means having consistent clinical support: someone to call when you're not sure whether what you're experiencing is normal, and a prescriber who reviews your progress before each dose increase rather than after a problem has developed.
Many people start looking at where to source Mounjaro and focus on price as the main variable. The clinical oversight wrapped around a prescription matters at least as much. A service with no aftercare leaves you Googling your symptoms at 9 pm on a Saturday; one with genuine prescriber support means you have somewhere to turn. If you're weighing up your options and want to understand what a properly supervised private treatment looks like, the treatment overview at nume explains what is included at each stage. You may also find it useful to read about whether Mounjaro can help with anxiety, as some people notice changes in mood and mental wellbeing alongside the physical side effects during treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.